51 results
S-3
PASG
Passage Bio Inc
4 Mar 24
Shelf registration
4:09pm
utility of our product candidates, our commercialization, marketing and manufacturing capabilities and strategy, our expectations about the willingness
8-K
EX-99.1
PASG
Passage Bio Inc
20 Dec 23
Passage Bio Announces Promising Initial Data from Phase 1/2 Clinical Trial of PBFT02 In FTD-GRN and Updated Strategic Priorities
7:05am
., president and chief executive officer at Passage Bio. “As we pursue this strategy, we are actively exploring potential partnerships to advance our GM1 … gangliosidosis program as well as our other clinical-stage pediatric programs. This shift in strategy aims to optimize focus and resources and provides each
8-K
yj7nbck2j
20 Jul 23
Departure of Directors or Certain Officers
7:00am
PRE 14A
qpfdjt5m0dcgodjojud
3 Apr 23
Preliminary proxy
4:05pm
8-K
EX-99.2
7ynv0tm
10 Nov 22
Passage Bio Reports Third Quarter 2022 Financial Results And Provides Business Updates
7:03am
8-K
EX-99.1
1l09vt0v xpw2tkr0
10 Nov 22
Passage Bio Reports Third Quarter 2022 Financial Results And Provides Business Updates
7:03am
8-K
7gx kahlm
11 Oct 22
Departure of Directors or Certain Officers
7:15am
8-K
EX-99.2
f6ts l611
4 Aug 22
Passage Bio Reports Second Quarter 2022 Financial Results and Provides Recent Business Highlights
7:20am
8-K
rrx0v yob63
1 Jun 22
Departure of Directors or Certain Officers
8:00am
8-K
EX-99.2
c7p0y
16 May 22
Passage Bio Reports First Quarter 2022 Financial Results and Provides Recent Business Highlights
7:15am